FCR-CM101-100μg / 询价
FCR-CM101-500μg / 询价
FCR-CM101-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Cynomolgus FcRH5/FcRL5 Protein
Recombinant Cynomolgus FcRH5/FcRL5 Protein is expressed from HEK293 with His tag at the C-terminus.It contains Gln16-Gly851 [Accession | XP_005541423.2].
The protein has a predicted MW of 92.13 kDa. Due to glycosylation, the protein migrates to 100-130 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus FcRH5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Anti-FcRH5 Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Cynomolgus FcRH5, His Tag with the EC50 of 0.54μg/ml determined by ELISA (QC Test).
Cynomolgus FcRH5, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-FcRH5 Ab., hFc Tag with an affinity constant of 0.14 μM as determined in SPR assay (Biacore T200).
Loaded Anti-FcRH5 Antibody, hFc Tag on ProA-Biosensor can bind Cynomolgus FcRH5, His Tag with an affinity constant of 0.10 µM as determined in BLI assay (Gator® Prime).
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2
(1)Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163.MCT-12-0087.
